Proprietary warehouses delivered scale — but at the cost of control, predictable pricing, and real flexibility. Enterprises are doing the math.

Sanofi has said it plans to start discussions about filing its oral BTK inhibitor tolebrutinib for multiple sclerosis, even though the drug only achieved its primary objective in one of three phase 3 ...